Ddavp Is 0.1 mg / 1ml Intranasal Solution
PDF Leaflet Revision Date: 30 July 2007
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of vasopressin sensitive central diabetes insipidus.
Dosage (summary)
Adults: 10-20 u03bcg intranasally 1-2 times daily.
Onset of Action / Duration
Onset: 2 hours, Duration: 4-8 hours
Special Populations
- Elderly
- Children
- Renal impairment
Pregnancy & Breastfeeding
Safety in pregnancy and lactation not established; minimal transfer to breast milk.
Key Drug Interactions
- Tricyclic antidepressants
- SSRIs
- NSAIDs
- Carbamazepine
Contraindications
- Renal diabetes insipidus
- Hypersensitivity
- Peripheral vascular disease
- Cardiac insufficiency
- Cirrhosis
- Hypertension
- SIADH
Common side effects
- Nasal congestion
- Epistaxis
- Abdominal pain
- Nausea
- Headache
Counselling Points
- Limit fluid intake before and after administration
- Monitor for signs of hyponatraemia
- Use under adult supervision in children
Serious warnings
- Risk of overhydration
- Monitor fluid intake
- Caution in elderly and children
Important Disclaimer
The Ddavp Is 0.1 mg / 1ml Intranasal Solution professional information leaflet below is the property of Ferring and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
